VOLATILITY ASSET - $UVXY - EW Forecast - BLOOD MOON
Updated
Here is my Model Forecast for UVXY:
Strategy:
- Entry: 7.2
- SL: 4.4
- Wave 3 PT: 207
- Wave 5 PT: 334
- RRR: 116
- Timeframe: 1 year
Trading the Blood Moon.
Strategy:
- Entry: 7.2
- SL: 4.4
- Wave 3 PT: 207
- Wave 5 PT: 334
- RRR: 116
- Timeframe: 1 year
Trading the Blood Moon.
Note
Spotshooter1983:Yes fund families and broker dealers trade their own accounts.
And yes they likely are buying puts and short the UVXY common continually.
why not if you have the capital to not be concerned about the occasional bump to $38 (Volmageddon 2018) or $130 ( Covid crisis drop March 2021)?
A fund that has capital does not have to worry about a short squeeze absent a GameStop subReddit WSB raid.
Likely UVXY is continually short in ProShares. private accounts and institutional accounts the company handles.
Favorite old book title "Where are the Customers Yachts?"
Hmmm
Wonder what that means?
UVXY is always downward with occasional spikes. This week it is more volatile to the downside. Is that by ProShares to quickly facilitate the reverse split?
Ok I could believe that.
But it's just part of the game.
Game it.
Its always down absent the occasional spike.
Maybe this week a good thesis would be ....at $8 ALWAYS buy puts that are 30 delta and slightly in the money. Or some vsristion of that. Put it in your playbook for the next time to consider and watch for that possibility. I certainly will.
Every time I don't get paid I should learn from it. I make it a mindfulness experience by reversing the positions. I don't grumble about ProShares.
I ask...
What would I be doing if I were ProShares trading the corporate account?
Note
DPT:and what if there was an actor that had even more capital, who would benefit from a major increase in volatility, and a crash of the US economy? Would it be a good move for them to short squeeze such a fund?
Note
Another hint:
Note
Technical Analysis of UVXY (new public idea):
Trade active
Potential Black Swans and SP500:
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.